{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:54:10Z","timestamp":1791388450197,"version":"4.3.3"},"reference-count":35,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Intramyocardial haemorrhage (IMH) after reperfused ST-elevation myocardial infarction is associated with adverse outcomes, yet no therapy specifically targets it. Dexrazoxane (DXZ) may mitigate iron-mediated injury from IMH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SHIELD-MI was a single-centre, non-randomized, placebo-controlled, sequential-cohort phase IIa study with participants and the cardiac MRI (CMR) core laboratory blinded to treatment. Twenty-five patients received intravenous DXZ 250 mg before primary percutaneous coronary intervention and at 4, 8, and 12 h thereafter. Twenty-five comparators, selected from 78 placebo-treated patients, were matched on total ischaemic time, culprit territory, and pre-percutaneous coronary intervention occlusion status. Primary endpoints were left ventricular ejection fraction (LVEF) and IMH volume on CMR at 48\u201372 h, evaluating early ventricular function and haemorrhagic myocardial injury after reperfusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the matched analytic cohort (n = 50), LVEF was higher in patients receiving DXZ (39.8 \u00b1 7.7% vs 34.7 \u00b1 10.1%; P = .048), permitting formal testing of IMH volume, which was lower with DXZ (2.0 \u00b1 3.4% LV vs 6.3 \u00b1 6.0% LV; P = .004). The prespecified fixed-sequence criterion was therefore met at both steps. Infarct size was lower with DXZ (29.1 \u00b1 13.1% LV vs 43.8 \u00b1 18.6% LV; P = .002). Haemorrhagic MI occurred in 6\/25 (24%) vs 16\/25 (64%) participants (P = .010). No drug-related serious adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Peri-procedural intravenous DXZ was associated with lower IMH and infarct size and higher LVEF, without safety concerns. These exploratory findings identify IMH as a candidate therapeutic target warranting a randomized trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag715","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:24:47Z","timestamp":1787570687000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-9479","authenticated-orcid":false,"given":"Keyur P","family":"Vora","sequence":"first","affiliation":[{"name":"Cardiovascular Imaging Research Center, Medical Imaging Research Institute, Department of Radiology & Imaging Sciences, Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]},{"name":"Synergy Cardiovascular Research Center, Department of Cardiology, Synergy Superspecialty Hospital , Rajkot, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Synergy Cardiovascular Research Center, Department of Cardiology, Synergy Superspecialty Hospital , Rajkot, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrenik","family":"Doshi","sequence":"additional","affiliation":[{"name":"Synergy Cardiovascular Research Center, Department of Cardiology, Synergy Superspecialty Hospital , Rajkot, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Poptani","sequence":"additional","affiliation":[{"name":"Synergy Cardiovascular Research Center, Department of Cardiology, Synergy Superspecialty Hospital , Rajkot, Gujarat ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Health Sciences North and Northern Ontario School of Medicine University , Sudbury, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Finney","sequence":"additional","affiliation":[{"name":"Cardio-Theranostics LLC , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Taub","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, State University of New York (SUNY) Upstate Medical University , Syracuse, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-7426","authenticated-orcid":false,"given":"Rishi","family":"Puri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Tamarappoo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Fry","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ascension St. Vincent Heart Center , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Henry","sequence":"additional","affiliation":[{"name":"The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Traverse","sequence":"additional","affiliation":[{"name":"Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0080-1660","authenticated-orcid":false,"given":"Ankur","family":"Kalra","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, State University of New York (SUNY) Upstate Medical University , Syracuse, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-4635","authenticated-orcid":false,"given":"Rohan","family":"Dharmakumar","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Medical Imaging Research Institute, Department of Radiology & Imaging Sciences, Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026100711214783100_ehag715-B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ib\u00e1\u00f1ez","year":"2018","journal-title":"Eur Heart J"},{"key":"2026100711214783100_ehag715-B2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026100711214783100_ehag715-B3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460","article-title":"Mortality associated with heart failure after myocardial infarction: a contemporary community perspective","volume":"9","author":"Gerber","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026100711214783100_ehag715-B4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"key":"2026100711214783100_ehag715-B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJM197107152850301","article-title":"Myocardial changes associated with cardiogenic shock","volume":"285","author":"Page","year":"1971","journal-title":"N Engl J Med"},{"key":"2026100711214783100_ehag715-B6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jcmg.2014.05.010","article-title":"Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients","volume":"7","author":"van Kranenburg","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/heart.87.2.162","article-title":"The \u201cno-reflow\u201d phenomenon: basic science and clinical correlates","volume":"87","author":"Reffelmann","year":"2002","journal-title":"Heart"},{"key":"2026100711214783100_ehag715-B8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/eurheartj\/ehv484","article-title":"Coronary microvascular obstruction in acute myocardial infarction","volume":"37","author":"Niccoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2026100711214783100_ehag715-B9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2011.08.016","article-title":"Detection and quantification of myocardial reperfusion hemorrhage using T2*-weighted CMR","volume":"4","author":"Kumar","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1148\/radiol.13122397","article-title":"Detection of acute reperfusion myocardial hemorrhage with cardiac MR imaging: T2 versus T2*","volume":"269","author":"Kali","year":"2013","journal-title":"Radiology"},{"key":"2026100711214783100_ehag715-B11","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1093\/eurheartj\/eht100","article-title":"Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and hemorrhage","volume":"34","author":"Robbers","year":"2013","journal-title":"Eur Heart J"},{"key":"2026100711214783100_ehag715-B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2022.100444","article-title":"Impact of intramyocardial hemorrhage on clinical outcomes in ST-elevation myocardial infarction: a systematic review and meta-analysis","volume":"1","author":"Vyas","year":"2022","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2026100711214783100_ehag715-B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004148","article-title":"Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance","volume":"9","author":"Carrick","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cjca.2023.09.020","article-title":"The Canadian Cardiovascular Society classification of acute atherothrombotic myocardial infarction based on stages of tissue injury severity: an expert consensus statement","volume":"40","author":"Kumar","year":"2024","journal-title":"Can J Cardiol"},{"key":"2026100711214783100_ehag715-B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jacc.2021.10.034","article-title":"Intramyocardial hemorrhage and the \u201cwave front\u201d of reperfusion injury compromising myocardial salvage","volume":"79","author":"Liu","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100711214783100_ehag715-B16","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400294","article-title":"In-hospital mortality in hemorrhagic myocardial infarction","volume":"4","author":"Vora","year":"2025","journal-title":"NEJM Evid"},{"key":"2026100711214783100_ehag715-B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.004996","article-title":"Persistent microvascular obstruction after myocardial infarction culminates in the confluence of ferric iron oxide crystals, proinflammatory burden, and adverse remodelling","volume":"9","author":"Kali","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B18","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.1038\/s41467-022-33776-x","article-title":"Intramyocardial hemorrhage drives fatty degeneration of infarcted myocardium","volume":"13","author":"Cokic","year":"2022","journal-title":"Nat Commun"},{"key":"2026100711214783100_ehag715-B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.004940","article-title":"Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling","volume":"9","author":"Bulluck","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa1505489","article-title":"Cyclosporine before PCI in patients with acute myocardial infarction","volume":"373","author":"Cung","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100711214783100_ehag715-B21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","article-title":"Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia","volume":"5","author":"L\u00f8nborg","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2026100711214783100_ehag715-B22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","article-title":"Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial","volume":"128","author":"Ibanez","year":"2013","journal-title":"Circulation"},{"key":"2026100711214783100_ehag715-B23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jcmg.2017.01.008","article-title":"Myocardial infarct size by CMR in clinical cardioprotection studies: insights from randomized controlled trials","volume":"10","author":"Bulluck","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100711214783100_ehag715-B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.yjmcc.2022.11.001","article-title":"Iron homeostasis in the heart: molecular mechanisms and pharmacological implications","volume":"174","author":"Zhang","year":"2023","journal-title":"J Mol Cell Cardiol"},{"key":"2026100711214783100_ehag715-B25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/CIRCINTERVENTIONS.111.966226","article-title":"Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation myocardial infarction","volume":"5","author":"Chan","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2026100711214783100_ehag715-B26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCRESAHA.112.300627","article-title":"Current state of clinical translation of cardioprotective agents for acute myocardial infarction","volume":"113","author":"Kloner","year":"2013","journal-title":"Circ Res"},{"key":"2026100711214783100_ehag715-B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0891-5849(89)90099-3","article-title":"Early treatment with deferoxamine limits myocardial ischemic\/reperfusion injury","volume":"7","author":"Reddy","year":"1989","journal-title":"Free Radic Biol Med"},{"key":"2026100711214783100_ehag715-B28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2174\/138920112802273245","article-title":"Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics","volume":"13","author":"Doroshow","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"2026100711214783100_ehag715-B29","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol"},{"key":"2026100711214783100_ehag715-B30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12968-021-00779-4","article-title":"Quantification of myocardial hemorrhage using T2* cardiovascular magnetic resonance at 1.5T with ex-vivo validation","volume":"23","author":"Chen","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026100711214783100_ehag715-B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12968-021-00787-4","article-title":"Assessment of intramyocardial hemorrhage with dark-blood T2*-weighted cardiovascular magnetic resonance","volume":"23","author":"Guan","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026100711214783100_ehag715-B32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/annonc\/mdl413","article-title":"Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies","volume":"18","author":"Mouridsen","year":"2007","journal-title":"Ann Oncol"},{"key":"2026100711214783100_ehag715-B33","first-page":"301","article-title":"Determinants of hemorrhagic infarcts. Histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion","volume":"137","author":"Garcia-Dorado","year":"1990","journal-title":"Am J Pathol"},{"key":"2026100711214783100_ehag715-B34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology"},{"key":"2026100711214783100_ehag715-B35","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag715\/70825985\/ehag715.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag715\/70825985\/ehag715.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag715\/70825985\/ehag715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:21:54Z","timestamp":1791386514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag715\/8772199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag715","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"ehag715"}}